This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Gilead, Bristol-Myers file reply brief backing dismissal of claims in HIV-drug antitrust case

( January 7, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Gilead and Bristol-Myers Squibb filed a reply brief in support of dismissing KPH Healthcare Services and FWK Holdings’ antitrust claims over a combination antiretroviral therapy used to treat human immunodeficiency virus. They said KPH and FWK’s purchase agreements contain broad pre-suit alternative dispute resolution provisions that apply and neither plaintiff complied with their obligations before filing their claims.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents